Iradimed Co

Company Profile

Iradimed Co had its IPO on 2014-07-16 under the ticker symbol IRMD.

The company operates in the Healthcare sector and Medical Devices industry. Iradimed Co has a staff strength of 123 employees.

Stock update

Shares of Iradimed Co opened at $47.12 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $43.44 - $47.18, and closed at $43.68.

This is a -7% slip from the previous day's closing price.

A total volume of 27,933 shares were traded at the close of the day’s session.

In the last one week, shares of Iradimed Co have slipped by -8.91%.

Iradimed Co's Key Ratios

Iradimed Co has a market cap of $591.95 million, indicating a price to book ratio of 5.1727 and a price to sales ratio of 7.1083.

In the last 12-months Iradimed Co’s revenue was $59.88 million with a gross profit of $41.28 million and an EBITDA of $17.47 million. The EBITDA ratio measures Iradimed Co's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Iradimed Co’s operating margin was 28.99% while its return on assets stood at 13.81% with a return of equity of 21.77%.

In Q2, Iradimed Co’s quarterly earnings growth was a positive 27.9% while revenue growth was a positive 26.8%.

Iradimed Co’s PE and PEG Ratio

Forward PE

23.9234

Trailing PE

40.4914

PEG

4.46

Its diluted EPS in the last 12-months stands at $1.16 per share while it has a forward price to earnings multiple of 23.9234 and a PEG multiple of 4.46. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Iradimed Co’s profitability.

Iradimed Co stock is trading at a EV to sales ratio of 6.1136 and a EV to EBITDA ratio of 18.9477. Its price to sales ratio in the trailing 12-months stood at 7.1083.

Iradimed Co stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 82.68%.

Balance sheet and cash flow metrics

Total Assets

$81.43 million

Total Liabilities

$7.59 million

Operating Cash Flow

$-378314.00

Capital Expenditure

$378314

Dividend Payout Ratio

82.68%

Iradimed Co ended 2024 with $81.43 million in total assets and $0 in total liabilities. Its intangible assets were valued at $81.43 million while shareholder equity stood at $69.00 million.

Iradimed Co ended 2024 with $0 in deferred long-term liabilities, $7.59 million in other current liabilities, 1260.00 in common stock, $41.63 million in retained earnings and $0 in goodwill. Its cash balance stood at $45.82 million and cash and short-term investments were $45.82 million. The company’s total short-term debt was $413,745 while long-term debt stood at $0.

Iradimed Co’s total current assets stands at $66.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $11.08 million compared to accounts payable of $2.55 million and inventory worth $8.42 million.

In 2024, Iradimed Co's operating cash flow was $-378314.00 while its capital expenditure stood at $378314.

Comparatively, Iradimed Co paid $0.83 in dividends in 2024.

Other key metrics

Current Trading Price

$43.68

52-Week High

$51.037

52-Week Low

$25.2265

Analyst Target Price

$57

Iradimed Co stock is currently trading at $43.68 per share. It touched a 52-week high of $51.037 and a 52-week low of $51.037. Analysts tracking the stock have a 12-month average target price of $57.

Its 50-day moving average was $46.94 and 200-day moving average was $40.46 The short ratio stood at 2.19 indicating a short percent outstanding of 0%.

Around 4274.2% of the company’s stock are held by insiders while 4765.1% are held by institutions.